Optus Pharmaceutical옵투스제약

Optus Pharmaceutical's trailing profit is well above its operating income, while free cash flow is deeply negative and the share price is down 9.4% over one year.

Optus Pharmaceutical reported trailing revenue of ₩94.5B to H1 2026, with operating income of ₩10.1B and net income of ₩12.4B. Revenue has grown from ₩57.3B in 2021, though operating margin has slipped from 18.3% to 10.7%. Trailing free cash flow is negative at -₩33.7B, and the company profile was not included in the data.

What stands out

• Trailing net income (₩12.4B) exceeds operating income (₩10.1B), which the data does not explain; the gap may reflect non-operating items, but this is not confirmed in the pack.
• Annual revenue grew 23.5% in 2023 and 13.1% in 2024 but only 6.4% in 2025, and operating margin has declined from 11.3% in 2023 to 10.2% in 2025.
• Trailing free cash flow of -₩33.7B contrasts with cash of ₩7.0B and no borrowings listed, so cash burn is a key figure to check.
• At ₩6,050 the stock trades at 8.6x trailing P/E and 0.6x P/B, with a 52-week range of ₩4,610 to ₩20,750 and a 1-year return of -9.4%.
• Recent filings include a half-year report (Aug 2026), a corrected new facility investment disclosure (Jun 2026), and an insider shareholding report, while a 불성실공시법인 (unfaithful disclosure) designation was reserved in May 2026 and later deferred.

What to watch

• Free cash flow and how the company funds its negative cash flow, given the ₩7.0B cash balance.
• The details and correction of the new facility investment filing from June 2026, which the pack does not describe.
• Status of the 불성실공시법인 designation process, and the next quarterly or annual results, which are not yet in the data.